<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Salakos, N.</style></author><author><style face="normal" font="default" size="100%">Kountouris, A.</style></author><author><style face="normal" font="default" size="100%">Botsis, D.</style></author><author><style face="normal" font="default" size="100%">Rizos, D.</style></author><author><style face="normal" font="default" size="100%">Gregoriou, O.</style></author><author><style face="normal" font="default" size="100%">Detsis, G.</style></author><author><style face="normal" font="default" size="100%">Creatsas, G.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">First-trimester pregnancy termination with 800 microg of vaginal misoprostol every 12 h.</style></title><secondary-title><style face="normal" font="default" size="100%">The European journal of contraception &amp; reproductive health care : the official journal of the European Society of Contraception</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Abortifacient Agents</style></keyword><keyword><style  face="normal" font="default" size="100%">Abortion</style></keyword><keyword><style  face="normal" font="default" size="100%">Administration</style></keyword><keyword><style  face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style  face="normal" font="default" size="100%">Adult</style></keyword><keyword><style  face="normal" font="default" size="100%">Drug Administration Schedule</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">First</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Induced</style></keyword><keyword><style  face="normal" font="default" size="100%">Induced: methods</style></keyword><keyword><style  face="normal" font="default" size="100%">Intravaginal</style></keyword><keyword><style  face="normal" font="default" size="100%">Misoprostol</style></keyword><keyword><style  face="normal" font="default" size="100%">Misoprostol: administration &amp; dosage</style></keyword><keyword><style  face="normal" font="default" size="100%">Misoprostol: adverse effects</style></keyword><keyword><style  face="normal" font="default" size="100%">Nonsteroidal</style></keyword><keyword><style  face="normal" font="default" size="100%">Nonsteroidal: administration</style></keyword><keyword><style  face="normal" font="default" size="100%">Nonsteroidal: adverse effect</style></keyword><keyword><style  face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style  face="normal" font="default" size="100%">Pregnancy Trimester</style></keyword><keyword><style  face="normal" font="default" size="100%">Treatment Outcome</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2005</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2005///</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/pubmed/16448952</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">10</style></volume><pages><style face="normal" font="default" size="100%">249 - 54</style></pages><isbn><style face="normal" font="default" size="100%">1362518050</style></isbn><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">The objective of the study was to evaluate the efficacy and safety of 800 microg of misoprostol every 12 h, for a period of 36 h for pharmacological abortion. A group of 162 volunteer women with gestations between 50 and 63 days received misoprostol every 12 h up to a maximum of three doses for abortion. Outcome measures assessed included: successful abortion (complete abortion without requiring surgery), side effects, and a decrease in hemoglobin, mean time of vaginal bleeding, mean expulsion time and mean time of returning of menses. Complete abortion occurred in 148 of 162 (91%, 95% confidence interval 87.95) patients. The mean decrease in hemoglobin was statistically significant (p = 0.001). Vaginal bleeding lasted 8.0 +/- 3.2 days, spotting 8.0 +/- 3.5 days, and total bleeding 16 +/- 4.0 days. The mean expulsion time was 8.5 +/- 4.0 h. According to the observed outcomes, 800 microg of misoprostol vaginally could be a valid method to terminate pregnancies up to 9 weeks of gestation.</style></abstract><issue><style face="normal" font="default" size="100%">4</style></issue></record></records></xml>